Athira Pharma is a clinical stage therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer's disease and Parkinson's disease.
Athira Pharma is striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s.
Athira Pharma was founded in 2011. The company is headquartered in Seattle, Washington.
Athira Pharma's innovative approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function. Athira is currently advancing its lead therapeutic candidate, NDX-1017, a novel small molecule, in later-stage clinical trials for Alzheimer's.
Athira Pharma is dedicated to impacting the course of neurodegenerative diseases and are eager to advance our lead therapeutic candidate, NDX-1017, into Phase 2/3 clinical development following the encouraging data we presented at CTAD, showing a rapid and statistically significant improvement in an objective measure of cognitive process in Alzheimer's patients.
Athira Pharma is backed by Perceptive Advisors, RTW Investments, Viking Global Investors, Venrock Healthcare Capital Partners, Franklin Templeton, Rock Springs Capital, Sofinnova Investments and others. The company raised $85M in Series B round on June 04, 2020. This brings Athira's total funding to $115.1M to date.